These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 24317203

  • 1. Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition.
    Yang Y, Qin SK, Wu Q, Wang ZS, Zheng RS, Tong XH, Liu H, Tao L, He XD.
    Oncol Rep; 2014 Feb; 31(2):540-50. PubMed ID: 24317203
    [Abstract] [Full Text] [Related]

  • 2. [Effects of all-trans retinoic acid on expression of connexin genes and gap junction communication in hepatocellular carcinoma cell lines].
    Liu YB, Xu B, Wang JW, Fang HQ, Li JT, Li HJ, Tang Z, Qian HR, Feng XD, Peng SY.
    Zhonghua Yi Xue Za Zhi; 2005 Jun 01; 85(20):1414-8. PubMed ID: 16029656
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Modifying gap junction communication in cancer therapy.
    Warawdekar UM, Jain V, Patel H, Nanda A, Kamble V.
    Curr Res Transl Med; 2021 Jan 01; 69(1):103268. PubMed ID: 33069641
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.
    Xu YY, Chen L, Wang GL, Zhou JM, Zhang YX, Wei YZ, Zhu YY, Qin J.
    BMC Cancer; 2013 Nov 06; 13():527. PubMed ID: 24195809
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
    Liu J, Liu Y, Meng L, Ji B, Yang D.
    Int J Med Sci; 2017 Nov 06; 14(6):523-529. PubMed ID: 28638267
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
    Honma Y, Shimizu S, Takehara T, Harada M.
    J Gastroenterol; 2014 Mar 06; 49(3):517-26. PubMed ID: 23543326
    [Abstract] [Full Text] [Related]

  • 20. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
    Kim JS, Choi GH, Jung Y, Kim KM, Jang SJ, Yu ES, Lee HC.
    J Cancer Res Clin Oncol; 2018 Aug 06; 144(8):1487-1501. PubMed ID: 29858683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.